Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma

Domenico Bellomo, PhD1; Suzette M. Arias-Mejias, BA2; Chandru Ramana, MS2; Joel B. Heim, PhD2; Enrica Quattrocchi, MD2; Sindhuja Somindir-Damodaran, MD2; Alina G. Bridges, DO2; Julia S. Lehman, MD2; Tina J. Hieken, MD2; James W. Jakub, MD2; Mark R. Pittelkow, MD2; David J. DiCaudo, MD2; Barbara A. Pockaj, MD2; Jason C. Sluzevich, MD4; Mark A. Cappel, MD4,5; Sanjay P. Bagaria, MD4; Charles Perniciaro, MD5; Félicia J. Tjian-Fooh, MS1; Martin H. van Vliet, PhD1; Jvalini Dwarkasing, PhD1; and Alexander Meves, MD2

abstract

PURPOSE More than 80% of patients who undergo sentinel lymph node (SLN) biopsy have no nodal metastasis. Here, we describe a model that combines clinicopathologic and molecular variables to identify patients with thin- and intermediate-thickness melanomas who may forgo the SLN biopsy procedure because of their low risk of nodal metastasis.

PATIENTS AND METHODS Genes with functional roles in melanoma metastasis were discovered by analysis of next-generation sequencing data and case-control studies. We then used polymerase chain reaction to quantify gene expression in diagnostic biopsy tissue across a prospectively designed archival cohort of 754 consecutive thin- and intermediate-thickness primary cutaneous melanomas. Outcome of interest was SLN biopsy metastasis within 90 days of melanoma diagnosis. A penalized maximum likelihood estimation algorithm was used to train logistic regression models in a repeated cross-validation scheme to predict the presence of SLN metastasis from molecular, clinical, and histologic variables.

RESULTS Expression of genes with roles in epithelial-to-mesenchymal transition (glia-derived nexin, growth differentiation factor 15, integrin-β3, interleukin 8, lysyl oxidase homolog 4, transforming growth factor-β receptor type 1, and tissue-type plasminogen activator) and melanosome function (melanoma antigen recognized by T cells 1) were associated with SLN metastasis. The predictive ability of a model that only considered clinicopathologic or gene expression variables was outperformed by a model that included molecular variables in combination with the clinicopathologic predictors Breslow thickness and patient age (area under the receiver operating characteristic curve, 0.82; 95% CI, 0.78 to 0.86; SLN biopsy reduction rate, 42%; negative predictive value, 96%).

CONCLUSION A combined model that included clinicopathologic and gene expression variables improved the identification of patients with melanoma who may forgo the SLN biopsy procedure because of their low risk of nodal metastasis.

JCO Precis Oncol 4:319-334. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License

INTRODUCTION Primary cutaneous melanoma staging by American Joint Committee on Cancer (AJCC) 8th edition guidelines is determined by whether the disease has spread to sentinel lymph nodes (SLNs).1,2 Large multicenter trials have shown that subclinical nodal metastasis is a pivotal prognostic marker3 and that SLN biopsy (SLNb) is the standard of care for patients with clinically node-negative melanoma.4 The likelihood of SLN metastasis is influenced by tumor thickness quantified as Breslow thickness and other adverse features, such as tumor ulceration and younger age. Rates of nodal metastasis range from 2.5% in very-thin, nonulcerated melanoma (< 0.75 mm Breslow thickness) to 32.9% in thick melanoma (> 3.5 mm Breslow thickness).3,5,6 At present, the only method to accurately determine nodal metastasis is the meticulous pathologic examination of surgically removed SLNs. Per current guidelines (Table 1), SLNb is not recommended if the risk of nodal metastasis is < 5%, as in melanoma with a Breslow thickness of < 0.8 mm and no adverse features. SLNb should be considered if the risk of nodal metastasis is between 5% and 10% (Breslow...
thickness, 0.8-1.0 mm) and is recommended if the risk of nodal metastasis exceeds 10% (Breslow thickness, 1.0 mm). Nodal metastasis is found in 20% of patients who undergo an SLNb. All patients who undergo SLNb face a 10% risk of short- and long-term complications, including bleeding, infection, lymphocele, lymphatic fistula, pain, neuropathy, and lymphedema, as well as an up to 5% risk of hospital readmission within 30 days because of postsurgical complications. Better methods are needed to identify patients whose risk of nodal metastasis is so low that they may safely forgo SLNb. Here, we report the design of a model that combines established clinicopathologic (CP) variables with a gene expression profile (GEP) to identify patients who have a risk of nodal metastasis of <5%. The CP-GEP model may help to identify patients who may forgo SLNb and target the procedure to those most likely to benefit.

**PATIENTS AND METHODS**

**Patient Cohort**

Our cohort consisted of 754 patients who had an SLNb performed within 90 days of their diagnosis (ie, a time interval shown to not affect SLNb positivity rates). Patients with primary cutaneous melanoma who presented at Mayo Clinic tertiary care centers in Minnesota, Arizona, or Florida between 2004 and 2018 with known SLN status were retrospectively identified by electronic searches of pathology reports. Charts were then reviewed for eligibility criteria (see next paragraph), and if met, diagnostic biopsy tissue was requested. Patients underwent SLNb between March 2004 and March 2018. Of the 754 patients in this cohort, 373 were included in a previously published cohort. All specimens were analyzed by quantitative polymerase chain reaction (PCR) between February 2018 and October 2018.

Eligibility was determined on the basis of histopathology data derived from patient medical records and established clinicopathologic (CP) variables, with a gene expression profile (GEP) to identify patients who may be at low risk of nodal metastasis. The CP-GEP model may help to identify patients whose risk of nodal metastasis is low.

**TABLE 1. SLNb National Comprehensive Cancer Network Guideline Recommendations**

| Probability of a Positive SLNb Finding (%) | T Category | Recommendations for SLNb |
|------------------------------------------|-----------|--------------------------|
| > 10%                                    | T1a: Breslow thickness > 0.8 mm, no ulceration and > 40 years | Not recommended |
| 5-10%                                    | T1a: Breslow thickness > 0.8 mm, with adverse features (eg, high mitotic rate) | T1b: Breslow thickness > 0.8 mm with ulceration |
| 10-30%                                   | T1b: Breslow thickness 0.8-1.0 mm |
| 30-50%                                   | T2a: Breslow thickness > 1.0 mm |

Abbreviation: SLNb, sentinel lymph node biopsy.

**Key Objective**

There can be uncertainty about whether a sentinel lymph node (SLN) biopsy is warranted in patients with cutaneous melanoma. Aggressive melanoma easily metastasizes, including to SLNs, and positive SLNs identify patients in need of adjuvant therapy. However, most melanomas do not metastasize to SLNs, and the removal of negative SLNs has no discernible therapeutic effect. The key objective of this study was to identify primary melanoma clinicopathologic (CP) variables and GEP that associate with a low risk of nodal metastasis.

**Knowledge Generated**

CP variables in combination with an eight-gene GEP tied to epithelial-to-mesenchymal transition as a biologic process inherent to metastasis effectively stratified melanoma according to its likelihood of SLN metastasis. Our CP-GEP model promises to work as an SLN biopsy reduction tool. Patients with negative results may forgo SLN biopsy because their risk of nodal metastasis is low.
Exclusion criteria were M1 disease within 90 days of primary diagnosis; insufficient primary tumor diagnostic biopsy tissue; inadequate RNA harvested; and, for Minnesota, denial of access to medical records for research purposes (per Minnesota State law). Because there is an ongoing debate about the relevance of <0.1 mm metastasis in SLN (ie, isolated tumor cells [ITCs] and cell clusters <0.1 mm in diameter), patients with <0.1 mm metastasis were excluded from model development. SLNs may harbor clusters of benign melanocytes, particularly in juxtaposition to the capsule. Isolated benign melanocytes and histiocytic melanophages can be present elsewhere in the SLN and mimic ITCs. Some authors cautioned against hidden tumor burden in <0.1 mm metastatic SLN and highlighted the need for enhanced pathology assessment protocols. Enrollment of patients and inclusion and exclusion criteria are summarized in Appendix Figure A1. Clinical variables used for statistical modeling are listed in Appendix Table A1. This study was approved by the Mayo Clinic institutional review board.

**Gene Expression by Quantitative PCR**

See the Appendix for details.

**Statistical Methods**

**Logistic regression and least absolute shrinkage and selection operator.** All classifiers were logistic regression models. Feature selection and parameter estimation were performed through a penalized maximum likelihood estimation algorithm through least absolute shrinkage and selection operator (LASSO). Models were constructed and analyzed in R 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria) with the package glmnet (version 2.0-16). LASSO was chosen to enhance the interpretability of the model by reducing the number of features while preserving the prediction accuracy. Gene expression input for the regression models was ΔCt. Categorical variables were represented through binary indicator variables. We detected and removed features with a high degree of collinearity using the R package olssr (version 0.5.1). Features with a tolerance ≤ 0.15 were removed from the input data set (the tolerance represents the fraction of variance in the kth feature that cannot be accounted for by other features). The output of logistic regression models estimated the probability of SLN metastasis and was converted into binary results. Samples with a probability of metastasis greater than the cutoff were classified as positive, whereas samples with a probability lower than the cutoff were classified as negative. The performance metrics of the classifiers are listed in Appendix Table A2 and are cutoff specific, except the area under the receiver operating characteristic curve (AUC).

**Double-loop cross-validation.** It is a common requirement in the medical literature that the performance of a new model be validated in a test set independent from the development set. However, splitting the available data just once into a training set and a test set may be viewed as inefficient. A better solution is to estimate the average performance of the model by repeated cross-validation or bootstrapping. Here, we opted for a repeated cross-validation scheme (ie, double-loop cross-validation [DLCV]). The key idea of DLCV is to get a reliable estimate of the out-of-sample performance of a classifier by averaging the performance of multiple classifiers trained in cross-validation a number of times (Appendix Fig A2). See the Appendix for details.

**Memorial Sloan Kettering Cancer Center Nomogram.** See the Appendix for details.

**RESULTS**

**Epithelial-to-Mesenchymal Transition in High-Risk Melanoma**

To identify candidate genes tied to biologic processes inherent to metastasis and differentially expressed between metastatic and nonmetastatic melanoma, we first reviewed RNA sequencing data obtained previously. Genes with a false discovery rate of <0.01 in a comparison of either benign nevi and cutaneous melanoma or cutaneous melanoma with and without SLN metastasis were selected for further qualification. A total of 194 candidate biomarkers and 3 control genes were screened for performance in Breslow thickness and age-matched case-control studies by quantitative PCR (Appendix Table A3). Of the candidate biomarkers, 108 were selected for further analysis in a prospectively designed archival cohort. We noted that genes predictive of nodal metastasis had been associated with epithelial-to-mesenchymal transition (EMT), a biologic process known to promote metastasis in primary cutaneous melanoma.

Our prospectively designed archival cohort comprised 754 patients with thin- and intermediate-thickness primary cutaneous melanoma who underwent an SLN biopsy within 90 days of diagnosis (Table 2). Of 754 patients, 128 (17%) were SLN positive, in agreement with the typical prevalence in an SLN-positive population. Our approach was to develop models of the likelihood of SLN metastasis on the basis of either CP variables (CP models) or GEPs of the primary tumor (GEP models) and then to assess the performance of a combined model of CP and GEP factors (CP-GEP models). All models were logistic regression models. Widely available CP factors considered included Breslow thickness, ulceration, mitotic rate, and patient age at diagnosis. Of these, LASSO selected Breslow thickness and patient age. More complex CP models did not improve performance (Appendix Fig A3). We therefore concluded that a CP model that is based on Breslow thickness and patient age is an adequate reference and that there is a limit to the ability of CP factors to predict SLN metastasis.
| Characteristic                        | Negative (n = 626) | Positive (n = 128) | P*     |
|--------------------------------------|-------------------|-------------------|--------|
| Male sex                             | 393 of 626 (62.8) | 79 of 128 (61.7)  | .82    |
| Mean age at SLNb, years (SD)         | 61.0 (15.87)      | 53.66 (17.11)     | < .001 |
| Biopsy location                      |                   |                   | .13    |
| Head and neck                        | 122 of 626 (19.5) | 26 of 128 (20.3)  |       |
| Trunk                                | 202 of 626 (32.3) | 49 of 128 (38.3)  |       |
| Upper extremity                      | 160 of 626 (25.6) | 19 of 128 (14.8)  |       |
| Lower extremity                      | 91 of 626 (14.5)  | 23 of 128 (18.0)  |       |
| Acral                                | 51 of 626 (8.1)   | 11 of 128 (8.6)   |       |
| Breslow thickness, mm                |                   |                   | < .001 |
| 0.50-1                               | 186 of 626 (29.7) | 6 of 128 (4.7)    |       |
| 1.01-2                               | 309 of 626 (49.4) | 50 of 128 (39.1)  |       |
| 2.01-4                               | 131 of 626 (20.9) | 72 of 128 (56.2)  |       |
| Clark level                          |                   |                   | < .001 |
| II                                   | 6 of 620 (1.0)    | 1 of 127 (0.8)    |       |
| III                                  | 148 of 620 (23.9) | 7 of 127 (5.5)    |       |
| IV                                   | 449 of 620 (72.4) | 118 of 127 (92.9) |       |
| V                                    | 17 of 620 (2.7)   | 1 of 127 (0.8)    |       |
| Mitotic rate type                    |                   |                   | < .001 |
| Absent                               | 92 of 623 (14.8)  | 4 of 127 (3.1)    |       |
| 1-6                                  | 430 of 623 (69.0) | 82 of 127 (64.6)  |       |
| > 6                                  | 101 of 623 (16.2) | 41 of 127 (32.3)  |       |
| Ulceration                           | 114 of 622 (18.3) | 46 of 128 (35.9)  | < .001 |
| Angiolympathic invasion              | 19 of 526 (3.0)   | 16 of 111 (12.5)  | < .001 |
| Regression                           | 47 of 518 (9.1)   | 6 of 109 (5.5)    | .22    |
| Tumor-invading lymphocytes           |                   |                   | .04    |
| Absent                               | 140 of 550 (25.5) | 30 of 113 (26.5)  |       |
| Nonbrisk                             | 302 of 550 (54.9) | 72 of 113 (63.7)  |       |
| Brisk                                | 108 of 550 (19.6) | 11 of 113 (9.7)   |       |
| Microsatellitosis                    | 2 of 493 (0.4)    | 2 of 107 (1.9)    | .09    |
| Histologic type                      |                   |                   |       |
| Superficial spreading                | 336 of 626 (53.7) | 63 of 128 (49.2)  |       |
| Nodular                              | 112 of 626 (17.9) | 38 of 128 (29.7)  |       |
| Desmoplastic                         | 18 of 626 (2.9)   | 0                 |       |
| Lentigo maligna                      | 32 of 626 (5.1)   | 0                 |       |
| Acral lentiginous                     | 11 of 626 (1.8)   | 4 of 128 (3.1)    |       |
| Spindled                             | 14 of 626 (2.2)   | 1 of 128 (0.8)    |       |
| Dermal                               | 3 of 626 (0.5)    | 0                 |       |
| Spitzoid                             | 5 of 626 (0.8)    | 1 of 128 (0.8)    |       |
| Neviod                               | 11 of 626 (1.8)   | 0                 |       |
| Unclassified                         | 43 of 626 (6.9)   | 13 of 128 (10.2)  |       |

(Continued on following page)
Using Gene Expression to Predict SLN Metastasis

DLCV and LASSO were used to identify a GEP defined from 11 genes that differentiated the patients with and without nodal metastasis detected by SLNb within 90 days of primary diagnosis: ADAM metallopeptidase domain 12 (ADAM12), interleukin 8 (CXCL8), growth differentiation factor 15 (GDF15), integrin-β3 (ITGB3), galectin 1 (LGALS1), lysyl oxidase like 4 (LOXL4), melanoma antigen recognized by T cells 1 (MLANA), tissue-type plasminogen activator (PLAT), protein kinase C-β (PRKCB), glia-derived nexin (SERPINE2), and transforming growth factor-β (TGF-β) receptor 1 (TGFBR1). Finally, logistic regression modeling was used to develop a novel model combining CP factors (ie, Breslow thickness and patient age) and a GEP. The combined CP-GEP model was based on the expression of MLANA, a melanosome marker,23 and seven genes functionally linked to EMT and with specific roles in angiogenesis/hypoxia and coagulation: GDF15,24-26 CXCL8,27,28 LOXL4,29,30 TGFBR1,31,32 ITGB3,33-36 PLAT,37,38 and SERPINE239,40 (Table 3). The overall discriminatory ability of the CP model (AUC, 0.78; 95% CI, 0.74 to 0.82) and GEP (AUC, 0.78; 95% CI, 0.73 to 0.82) was improved by combining CP factors and a GEP (AUC, 0.82; 95% CI, 0.78 to 0.86; Appendix Fig A4; Appendix Table A4).

Likewise, the combined CP-GEP model achieved an approximately 15% higher SLNb reduction rate compared with the benchmark CP model at a negative predictive value of 95% (Fig 1) as well as an almost 60% improvement over current clinical practice as listed in Table 1. The CP-GEP model, therefore, promised to work as an SLNb reduction tool: Patients with a negative test may forgo SLNb because their risk of nodal metastasis is, on average, < 5%, a reduction from the pre-test probability41 (Table 1).

For a predictor of SLN status to be clinically relevant, it must change the pretest probability within each T category of melanoma. T categorization provides a valuable risk prediction tool and is readily available in clinical practice. We therefore stratified results of the CP-GEP model by T category. SLNb reduction rates were highest for T1b melanoma at approximately 80% and then decreased as lesions became more advanced (Table 4). T2a melanoma still showed a considerable SLNb reduction rate of 48% while preserving a high negative predictive value of 95%. The high SLNb reduction rate for T1b melanoma is particularly meaningful in light of the increasing incidence of thinner melanoma,42 for which CP variables are less predictive.5

To further define the clinical relevance of the CP-GEP model, we compared CP-GEP performance to the well-known Memorial Sloan Kettering Cancer Center (MSKCC) nomogram for predicting SLN metastasis. The MSKCC nomogram is a graphical representation of a logistic regression model. It is based on five CP variables: patient age, Breslow thickness, Clark level, biopsy location, and tumor ulceration. We found

### Table 2. Patient and Tumor Characteristics Stratified by SLNb Outcome (Continued)

| Characteristic       | SLNb Outcome, No. (%) | P*  |
|----------------------|-----------------------|-----|
| Other                | 4 of 626 (0.6)        |     |
| Mixed                | 6 of 626 (1.0)        | 2 of 128 (1.6) |
| Not documented       | 31 of 626 (5.0)       | 6 of 128 (4.7) |

Abbreviations: SD, standard deviation; SLNb, sentinel lymph node biopsy.

*Comparisons of patients with SLNb-negative and -positive outcomes were performed using the χ² test for categorical variables, the two-sample t test for patient age, and the Wilcoxon rank sum test for all other variables.

### Table 3. Functional Roles of Genes in the Combined Clinicopathologic and Gene Expression Profile Model to Predict Sentinel Lymph Node Metastasis

| Gene (protein) | Gene Function |
|---------------|--------------|
| MLANA         | Melanosome biogenesis23 |
| GDF15         | EMT,24 angiogenesis,25 metabolism/cachexia26 |
| CXCL8         | EMT,27 angiogenesis28 |
| LOXL4         | EMT,29 angiogenesis30 |
| TGFBR1        | EMT,31 angiogenesis32 |
| ITGB3         | EMT,33 angiogenesis,34 cell adhesion and migration,35 blood coagulation36 |
| PLAT          | EMT,37 blood coagulation38 |
| SERPINE2      | EMT,39 blood coagulation40 |

Abbreviations: EMT, epithelial-to-mesenchymal transition; TGF-β, transforming growth factor-β.
that the MSKCC nomogram performed similarly to the CP model but was outperformed by the CP-GEP model in AUC (Appendix Fig A5) and SLNb reduction rate (Fig 2).

**DISCUSSION**

While completion lymphadenectomy for which SLNb was a key determinant has fallen out of favor,\(^43,44\) SLNb continues to determine patient eligibility for adjuvant therapy. Unfortunately, the majority of SLNb procedures performed today are negative, which confirms only the low-risk nature of the primary tumor without influencing decision making toward adjuvant therapy. Here, we present a model that considers gene expression and CP variables (ie, Breslow thickness and patient age) to assess the likelihood of SLN metastasis in patients diagnosed with thin- and intermediate-thickness primary cutaneous melanoma. The ability to characterize melanoma at the molecular level reduces the need for SLNb, a surgical procedure that carries a risk of complications.\(^7\) Our approach of combining CP factors with molecular profiling better identifies patients who may forgo the SLNb procedure because of their low risk of metastasis.

For melanoma with a 5%-10% chance of SLN metastasis (Breslow thickness, 0.8-1 mm), SLNb is optional but should be discussed with the patient.\(^45\) Even though SLNb in this risk group is optional, > 50% of affected patients in the United States undergo SLNb.\(^46\) The majority of these patients have negative SLNb findings, which highlights our current dilemma with melanoma risk stratification and the limitations of histopathology alone as a predictor of regional metastasis. Multivariable models have used Breslow thickness, tumor ulceration, and patient age to predict SLN status, with age being a negative predictor and Breslow thickness as well as tumor ulceration being strong positive predictors.\(^47-50\) Angiolymphatic invasion was also found to positively correlate with SLN metastasis in some models.\(^5,51\) The most ambitious CP models, such as those developed from a large bi-institutional series, achieved SLNb reduction rates of 18%-30%, with a negative predictive value

---

**TABLE 4.** Average Performance of the Combined Clinicopathologic and Gene Expression Profile Model, Across T Categories, Trained in Double-Loop Cross-Validation

| T Category | P | SY | SP | NPV (95% CI) | PPV | ACC | bACC | SLNb RR (95% CI) | ER |
|------------|---|----|----|-------------|-----|-----|------|-----------------|----|
| T1b        | 0.03 | 0.41 | 0.82 | 0.98 (0.95 to 1.00) | 0.07 | 0.80 | 0.61 | 0.80 (0.74 to 0.86) | 0.02 |
| T2a        | 0.13 | 0.80 | 0.53 | 0.95 (0.91 to 0.98) | 0.21 | 0.56 | 0.66 | 0.48 (0.42 to 0.54) | 0.03 |
| T2b        | 0.17 | 0.94 | 0.27 | 0.96 (0.91 to 1.00) | 0.21 | 0.38 | 0.66 | 0.24 (0.14 to 0.34) | 0.01 |
| T3a        | 0.31 | 0.99 | 0.12 | 0.98 (0.95 to 1.00) | 0.33 | 0.38 | 0.55 | 0.08 (0.03 to 0.12) | 0.00 |
| T3b        | 0.43 | 1.00 | 0.07 | 1.00 (0.97 to 1.00) | 0.45 | 0.47 | 0.54 | 0.04 (0.00 to 0.09) | 0.00 |

**NOTE.** The operating point of the model was determined in each training set to yield an NPV of 97.5% and was fixed to that value in the corresponding test set.

**Abbreviations:** ACC, accuracy; bACC, balanced accuracy; ER, error rate; NPV, negative predictive value; P, fraction of patients with positive sentinel lymph nodes (prevalence); PPV, positive predictive value; SLNb RR, sentinel lymph node biopsy reduction rate; SP, specificity; SY, sensitivity.
ranging from 93% to 97%.41 Attempts at implementing these models into clinical practice have failed because of their limited efficacy. In comparison, the CP plus molecular model developed here showed an SLN reduction rate of 42% at a negative predictive value of 96% (Appendix Table A4). LASSO applied to CP factors in this cohort identified Breslow thickness and patient age as sufficient for CP risk stratification. More complex CP models did not improve performance (Appendix Fig A3). There seems to be a clear limit in the ability of CP factors to predict SLN metastasis.

To improve the performance of predictive models, we developed a GEP from primary diagnostic biopsy tissue. GEP has been used successfully in breast cancer to individualize therapy.52 Previous research on gene expression in invasive breast cancer,53 prostate cancer,54 colon cancer,55 melanoma10 and other solid cancers56 has consistently demonstrated the upregulation of adhesion receptors and secreted factors that remodel the tumor microenvironment and are involved in EMT.10,53-57 Here, we confirmed this upregulation and found genes involved in EMT with specific roles in angiogenesis (growth differentiation factor 15,25 interleukin 8,28 lysyl oxidase homolog 4,58 TGF-β receptor type 1,32 and integrin β340) and coagulation (tissue-type plasminogen activator,38 and glia-derived nexin40) as well as the melanosome biogenesis marker melanoma antigen recognized by T cells 1 to be associated with SLN metastasis (Table 3). The functional roles of these genes have been demonstrated by genetic approaches52,34,38,59 and pharmacologic efficacy studies where the inhibition of integrin-β3 by cyclic peptide,60 TGF-β receptor type 1 by kinase inhibitor,61 and interleukin 8 by neutralizing antibody62 reduced tumor angiogenesis, tumor growth, and metastasis. Tumor vascularity in melanoma diagnostic biopsy tissue is well known to associate with nodal and distant metastasis but has been difficult to quantify in the past.63 Likewise, constitutive fibrinolytic activity in tumor tissue has been described as early as 191164 and attributed largely to plasminogen activators38 and other serine proteases, such as glia-derived nexin,65 which promote metastasis,66 disseminated intravascular coagulation, and bleeding in patients with metastatic cancer.57

A drawback of the simultaneous selection of CP variables and genes by our feature selection algorithm is the absence of established variables easily recognizable by clinicians, such as ulceration, in the CP-GEP model. Our retrospective study was also limited by referral bias and variations in pathologic assessment. The exclusion of patients with ambiguous < 0.1 mm metastasis from model development could have influenced the results. Moreover, we excluded T4 lesions (ie, melanoma with a Breslow thickness < 4 mm) because the pretest probability of regional metastasis for these patients is very high. For example, 21 (70%) of 30 patients with T4 lesions in our cohort presented with regional metastasis, which is well above the recommend threshold for recommending SLN. Clinicians may not want to forgo SLN for an a priori high-risk T4 melanoma, even if a molecular classifier was available. Finally, eligibility of patients with T1 melanoma was determined by the Mayo Clinic institutional practice guidelines for recommending SLN, which select for higher-risk patients, such as those < 40 years of age and with T1b melanoma. Indiscriminate inclusion of low-risk patients could have biased test performance calculations. For example, Vetto et al68 repurposed a molecular prognostic test to guide SLN decision making in T1-T2 melanomas: Patients with a negative test would forgo SLN in virtue of a nodal metastasis risk < 5% (negative predictive value > 95%). However, SLN to SLN metastasis risk was only < 5% if cohorts were enriched for a priori low-risk cases, such as by including T1a melanoma or restricting the analysis to patients > 65 years of age.

In summary, CP variables in combination with an eight-gene GEP tied to EMT as a biologic process inherent to metastasis effectively stratified patients with melanoma according to their likelihood of SLN metastasis. Previous attempts to develop molecular risk factors have been limited by small cohort sizes, incomplete TNM staging data, or limited clinical utility of the resulting models.49,69,70 Our approach of combining CP factors and gene expression variables improved the performance of CP factors alone by outperforming current clinical practice and important benchmarks, such as the MSKCC nomogram. The combined CP-GEP model maintained an average negative predictive value of > 95% across pathologic tumor thickness categories, which highlights its promise as a tool to identify low-risk patients who may forgo SLN. Our findings are particularly relevant to patients with thin- and intermediate-thickness melanoma who demonstrate significant heterogeneity in their SLN metastasis risk.2 Additional research is ongoing to externally validate our results.

**AFFILIATIONS**

1 SkylineDx, Rotterdam, the Netherlands
2 Mayo Clinic, Rochester, MN
3 Mayo Clinic, Scottsdale, AZ
4 Mayo Clinic, Jacksonville, FL
5 Gulf Coast Dermatopathology Laboratory, Tampa, FL

**CORRESPONDING AUTHOR**

Alexander Meves, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; Twitter: @MayoClinicCIM, @axm27; e-mail: meves.alexander@mayo.edu.

**PRIOR PRESENTATION**

Presented at the 15th European Association of Dermato-Oncology Congress, Paris, France, April 24-27, 2019.
SUPPORT
Supported by the National Cancer Institute (grant CA215105), National Center for Advancing Translational Sciences (grant UL1TR000135), Mayo Clinic Center for Individualized Medicine, Mayo Clinic Cancer Center, and the 5th District Eagles Cancer Telethon.

AUTHOR CONTRIBUTIONS
Conception and design: Domenico Bellomo, Suzette M. Arias-Mejias, Alina G. Bridges, Mark R. Pittelkow, Martin H. van Vliet, Jvalini Dwarkasing, Alexander Meves
Financial support: Alexander Meves
Administrative support: Mark R. Pittelkow, Alexander Meves
Provision of study material or patients: Alina G. Bridges, Tina J. Hieken, Mark R. Pittelkow, David J. DiCaudo, Barbara A. Pockaj, Mark A. Cappel, Charles Perniciaro, Alexander Meves
Collection and assembly of data: Suzette M. Arias-Mejias, Chandru Ramana, Joel B. Heim, Enrica Quattrocchi, Sindhuja Sominidi-Damodaran, Alina G. Bridges, Julia S. Lehman, James W. Jakub, Mark R. Pittelkow, David J. DiCaudo, Jason C. Sluzevich, Charles Perniciaro, Alexander Meves
Data analysis and interpretation: Domenico Bellomo, Suzette M. Arias-Mejias, Sindhuja Sominidi-Damodaran, Alina G. Bridges, Julia S. Lehman, Tina J. Hieken, James W. Jakub, Mark R. Pittelkow, Barbara A. Pockaj, Mark A. Cappel, Sanjay P. Bagaria, Felicia J. Tijen-Fooh, Martin H. van Vliet, Jvalini Dwarkasing, Alexander Meves
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Domenico Bellomo
Employment: SkylineDx
Stock and Other Ownership Interests: Synlogic, SkylineDX
Patents, Royalties, Other Intellectual Property: Gene signatures for predicting metastasis of melanoma

Julia S. Lehman
Patents, Royalties, Other Intellectual Property: Patent pending for molecular assay for graft-versus-host disease

Tina J. Hieken
Research Funding: Genentech (Inst), Roche (Inst)

Jason C. Sluzevich
Research Funding: Merck (Inst)

Charles Perniciaro
Honoria: Myriad Genetics
Travel, Accommodations, Expenses: Myriad Genetics

Felícia J. Tijen-Fooh
Employment: SkylineDx
Stock and Other Ownership Interests: SkylineDx

Martin H. van Vliet
Employment: SkylineDx
Stock and Other Ownership Interests: SkylineDx
Patents, Royalties, Other Intellectual Property: Named inventor on patents in the multiple myeloma field

Jvalini Dwarkasing
Employment: SkylineDx
Stock and Other Ownership Interests: SkylineDx

Alexander Meves
Research Funding: SkylineDx
Patents, Royalties, Other Intellectual Property: Mayo Clinic has filed several patent applications on which I am listed as an inventor; technologies are in the area of wound healing and skin cancer (Inst)
Open Payments Link: https://openpaymentsdata.cms.gov/physician/478139

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT
We thank Vera J. Suman, Amy L. Weaver, and Ruifeng Guo for helpful discussions and critical review of the manuscript. We thank Ming Li, Erica R. Leitzen, Carrie L. Kornegor, Vernadette A. Simon, and the Mayo Clinic Gene Expression Core Facility for excellent technical assistance.

REFERENCES
1. Saranga-Perry V, Ambe C, Zager JS, et al: Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin 64:171-185, 2014
2. Chang JM, Kosirek HE, Dueck AC, et al: Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg 215:699-706, 2018
3. Morton DL, Thompson JF, Cochran AJ, et al: Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599-609, 2014
4. Gershenwald JE, Scolyer RA, Hess KR, et al: Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin 67:472-492, 2017
5. Han D, Zager JS, Shyr Y, et al: Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 31:4387-4393, 2013
6. Hieken TJ, Grotz TE, Confare NI, et al: The effect of the AJCC 7th Edition change in T1 melanoma staging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma. Melanoma Res 25:157-163, 2015
7. Moody JA, Ali RF, Carbone AC, et al: Complications of sentinel lymph node biopsy for melanoma - A systematic review of the literature. Eur J Surg Oncol 43:270-277, 2017
8. Ascha M, Ascha MS, Gastman B: Identification of risk factors in lymphatic surgeries for melanoma: A national surgical quality improvement program review. Ann Plast Surg 79:509-515, 2017
9. Oude Ophuis CMC, Verhoef C, Rutkowski P, et al: The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study. Eur J Surg Oncol 42:1906-1913, 2016
10. Meves A, Nikolaou E, Heim JB, et al: Tumor cell adhesion as a risk factor for sentinel lymph node metastasis in primary cutaneous melanoma. J Clin Oncol 33:2509-2515, 2015
11. Yamamoto M, Fisher KJ, Wong YJ, et al: Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer 121:1629-1636, 2015
12. Fehily AS, Grotz TE, Keeneey GL, et al: Frozen section analysis of SLNs in trunk and extremity melanoma has a high false negative rate but can spare some patients a second operation. J Surg Oncol 114:870-883, 2016
13. Mahmood MN, Lee MW, Linden MD, et al: Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells. Mod Pathol 16:1288-1293, 2002
14. Murali R, DeSilva C, McCarthy SW, et al: Sentinel lymph nodes containing very small (<0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative. Ann Surg Oncol 19:1089-1099, 2012
15. Lobo AZ, Tanabe KK, Luo S, et al: The distribution of microscopic melanoma metastases in sentinel lymph nodes: Implications for pathology protocols. Am J Surg Pathol 36:1841-1848, 2012
16. van Ackooi ACJ, de Wilt JHW, Verhoef C, et al: Isolated tumor cells and long-term prognosis of patients with melanoma. Ann Surg Oncol 15:1547-1548, 2008
17. van Ackooi AC, de Witt JH, Verhoef C, et al: Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: Are these nodes to be considered negative? Ann Oncol 17:1578-1585, 2006
18. Tibshirani R: Regression selection and shrinkage via the LASSO. J R Stat Soc B 58:267-288, 1996
19. Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al: Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54:774-781, 2001
20. Wessels LF, Reinders MJ, Hart AA, et al: A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics 21:3765-3762, 2005
21. Alencio SR, Tracey L, Ortiz P, et al: A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67:3450-3460, 2007
22. Subramanian J, Simon R: What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol 7:327-334, 2010
23. Hoashi T, Watabe H, Muller J, et al: MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem 280:14006-14016, 2005
24. Li C, Wang J, Kong J, et al: GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget 7:860-872, 2016
25. Dong G, Zheng QD, Ma M, et al: Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15. Cancer Med 7:820-830, 2018
26. Mullican SE, Lin-Schmidt X, Chin CN, et al: GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 23:1150-1157, 2017
27. Fernando RI, Castillo MD, Litzinger M, et al: IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 71:5296-5306, 2011
28. Koch AE, Polverini PJ, Kunkel SL, et al: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801, 1992
29. Boufraqech M, Zhang L, Niubol N, et al: Lysyl oxidase (LOX) transcriptionally regulates SNAI2 expression and TIMP4 secretion in human cancers. Clin Cancer Res 22:4491-4504, 2016
30. Shih YH, Chang KW, Chen MY, et al: Lysyl oxidase and enhancement of cell proliferation and angiogenesis in oral squamous cell carcinoma. Head Neck 35:250-256, 2013
31. Singh A, Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29:4741-4751, 2010
32. Larsson J, Goumans MJ, Sjöstrand LJ, et al: Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 20:1663-1673, 2001
33. Cichon MA, Radisky DC: Extracellular matrix as a contextual determinant of transforming growth factor-β signaling in epithelial-mesenchymal transition and in cancer. Cell Adhes Migr 8:588-594, 2014
34. Mahabeleshwar GH, Feng W, Phillips DR, et al: Integrin signaling is critical for pathological angiogenesis. J Exp Med 203:2495-2507, 2006
35. Hood JD, Chereson DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100, 2002
36. Ni H, Freedman J: Platelets in hemostasis and thrombosis: Role of integrins and their ligands. Transfus Apheresis Sci 28:257-264, 2003
37. Shih YH, Chang KW, Chen MY, et al: Lysyl oxidase and enhancement of cell proliferation and angiogenesis in oral squamous cell carcinoma. Head Neck 35:250-256, 2013
38. Singh A, Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29:4741-4751, 2010
39. Larsson J, Goumans MJ, Sjöstrand LJ, et al: Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 20:1663-1673, 2001
40. Cichon MA, Radisky DC: Extracellular matrix as a contextual determinant of transforming growth factor-β signaling in epithelial-mesenchymal transition and in cancer. Cell Adhes Migr 8:588-594, 2014
41. Mahabeleshwar GH, Feng W, Phillips DR, et al: Integrin signaling is critical for pathological angiogenesis. J Exp Med 203:2495-2507, 2006
42. Hood JD, Chereson DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100, 2002
43. Ni H, Freedman J: Platelets in hemostasis and thrombosis: Role of integrins and their ligands. Transfus Apheresis Sci 28:257-264, 2003
44. Yang J, Shultz RW, Mars WM, et al: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110:1525-1538, 2002
45. Carmeliet P, Schoonjans L, Kieckens L, et al: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419-424, 1994
46. Mathias RA, Chen Y-S, Wang B, et al: Extracellular remodelling during oncogenic Ras-induced epithelial-mesenchymal transition facilitates MDCK cell migration. J Proteome Res 9:1007-1019, 2010
47. Baker JB, Low DA, Simmer RL, et al: Protease-nexin: A cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21:37-45, 1980
48. Mocellin S, Thompson JF, Pasquali S, et al: Sentinel node status prediction by four statistical models: Results from a large bi-institutional series (n = 1132). Ann Surg Oncol 17:1578-1585, 2006
49. Faries MB, Thompson JF, Cochran AJ, et al: Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:2211-2222, 2017
50. Coit D: The enigma of regional lymph nodes in melanoma. N Engl J Med 376:2280-2281, 2017
51. Wong SL, Faries MB, Kennedy EB, et al: Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. Ann Surg Oncol 25:356-377, 2018
52. Hayek SA, Munoz A, Dow J, et al: Hospital-based study of compliance with NCCN guidelines and predictive factors of sentinel lymph node biopsy in the setting of thin melanoma using the national cancer database. Am Surg 84:672-679, 2018
53. Maher AL, Compton C, Halabi S, et al: Critical assessment of clinical prognostic tools in melanoma. Ann Surg Oncol 23:2753-2761, 2016
54. Hanna AN, Sinnamon AJ, Roses RE, et al: Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00 mm): A National Cancer Database study. J Am Acad Dermatol 80:433-440, 2019
49. Conic RRZ, Ko J, Damiani G, et al: Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database. J Am Acad Dermatol 80:441-447, 2019
50. Cadili A, Dabbs K: Predictors of sentinel lymph node metastasis in melanoma. Can J Surg 53:32-36, 2010
51. Egger ME, Gilbert JE, Burton AL, et al: Lymphovascular invasion as a prognostic factor in melanoma. Am Surg 77:992-997, 2011
52. Sparano JA, Gray RJ, Makower DF, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111-121, 2018
53. Fina K, Bertos N, Pepin F, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518-527, 2008
54. Fraser M, Boutros PC, Bristow RG: A partner in crime: Tumor-associated stroma and metastatic prostate cancer. Eur Urol 73:533-534, 2018
55. Calon A, Lonardo E, Berenguer-Llergo A, et al: Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47:320-329, 2015
56. Kather JN, Charoentong P, Zoernig I, et al: Prognostic value of histopathological tumor-stroma ratio and a stromal gene expression signature in human solid tumors. J Clin Oncol 36, 2018 (suppl; abstr e24113)
57. Hamidi H, Ivaska J: Every step of the way: Integrins in cancer progression and metastasis. Nat Rev Cancer 18:533-548, 2018 [Erratum: Nat Rev Cancer 19:179, 2019]
58. Jiang WP, Sima ZH, Wang HC, et al: Identification of the involvement of LOXL4 in generation of keratocystic odontogenic tumors by RNA-Seq analysis. Int J Oral Sci 6:31-38, 2014
59. Rossaint J, Vestweber D, Zarbock A: GDF-15 prevents platelet integrin activation and thrombus formation. J Thromb Haemost 11:335-344, 2013
60. Abdollahi A, Griggs DW, Zieher H, et al: Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270-6279, 2005
61. Zhang M, Kleber S, Röhrich M, et al: Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:7155-7167, 2011
62. Huang S, Mills L, Mian B, et al: Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161:125-134, 2002
63. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al: Stromal gene expression in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 20:1826-1831, 2002
64. Carrel A, Burrows MT: Cultivation in vitro of malignant tumors. J Exp Med 13:571-575, 1911
65. Boulaftali Y, Ho-Tin-Noe B, Penaz A, et al: Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis. Circulation 123:1326-1334, 2011
66. Bugge TH, Lund LR, Kombrinck KK, et al: Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16:3097-3104, 1998
67. Naina HV, Patnaik MM, Ali UA, et al: Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. J Clin Oncol 28:e167-e168, 2010
68. Vetto JT, Hsu MH, Gastman BR, et al: Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol 15:1207-1217, 2019
69. Nye A, Collins JD, Porter CL, et al: Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: A case-matched pilot study. Melanoma Res 28:555-561, 2018
70. Marchetti MA, Bartlett EK, Dusza SW, et al: Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients? J Am Acad Dermatol 80:e161-e162, 2019
APPENDIX

Methods

Quantitative polymerase chain reaction (PCR) was performed as previously described.10 RNA purification was from formalin-fixed paraffin-embedded tissue (QIAGEN, Hilden, Germany). Quantitative reverse transcription PCR was done using the BioMark HD System and dynamic array integrated fluid circuits (Fluidigm, South San Francisco, CA). All cDNA was pre-amplified (TaqMan PreAmp Master Mix, Applied Biosystems, Foster City, CA). Array-based quantitative PCR was with the help of the TaqMan Gene Expression Master Mix (Applied Biosystems). After thermal cycling, raw Ct data were checked for linear amplification. Gene expression was corrected by the mean of housekeeping genes (RLP0, RLP8, and β-actin) using the ΔCt method.

Statistical Methods

Double-loop cross-validation. In the double-loop cross-validation scheme, there are two nested cross-validation loops. In the inner loop (10-fold cross-validation), we optimized the λ parameter by determining the number of features (ie, the weight of the least absolute shrinkage and selection operator penalty term), and in the outer loop (threefold cross-validation), we designed a classifier on the training set (two of the three folds). Next, we assessed the performance of the trained classifier on the remaining fold (test set), with the λ parameter fixed to the value estimated in the training set. The operating point of the classifier, as determined by a cutoff value on the estimated probability, was fixed to the training value as well. (We chose an operating point that yielded a negative predictive value of 97.5% in our cohort.) The cross-validation procedure was repeated 100 times. Unless otherwise stated, we report the average performance of 300 test sets (three test sets for each of the 100 repeats). The final classifiers were trained on the entire data set using the average λ parameter over 300 runs.

Memorial Sloan Kettering Cancer Center nomogram. The majority of online tools for melanoma provide prognostic information47 (Zabor et al: Ann Surg Oncol 25:2172-2177, 2018). The Memorial Sloan Kettering Cancer Center (MSKCC) nomogram, in contrast, is a tool specifically designed to predict the probability of primary cutaneous melanoma metastasis to SLN.23 The nomogram corresponds to a logistic regression model that is based on five clinicopathologic variables: age (range, 20-95 years), Breslow thickness (range, 0.1-10 mm), Clark level (II, III, IV, or V), biopsy location (trunk, extremity, or head and neck), and tumor ulceration (yes or no). The nomogram is accessible online (MSKCC: https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis). While attempting to apply the nomogram to our cohort, we could not calculate the probability of SLN metastasis for 16 patients because of missing values or because the values were outside the allowable range for the nomogram. Six patients were 20 years of age, seven had a missing Clark level (one of whom was also 20 years of age), and four did not have ulceration status available. Therefore, the analysis shown is based on 738 patients.

CIs. CIs for the area under the receiver operating characteristic curve were determined by the R package cvAUC (version 1.1.0); for the other metrics, they were determined by normal approximation interval when applicable or cross-validation estimates otherwise.
Total available patients (n = 855)

- Patients with primary cutaneous melanoma (N = 1,064)
- Unique Mayo Clinic patients (2004-2018)
  - SLNb within 90 days of the primary biopsy
  - No stage IV disease within 90 days of diagnosis
  - Breslow thickness ≥ 1 mm or 0.75-0.99 mm plus 1 RF* or 0.5-0.74 mm plus 2 RF*
- No research consent (n = 40)
- No tissue available for molecular analysis (n = 169)
- GEP assay failed: sample exhausted or not retrievable at time of analysis (n = 30)
- Patients with T4 lesions (Breslow thickness > 4 mm) (n = 30)
- < 0.1 mm metastasis in SLN (n = 41)

Discovery cohort (n = 754)

FIG A1. Study flow diagram. The figure depicts the enrollment of patients, inclusion and exclusion criteria, and other potential sources of retrospective bias such as the absence of research consent, the unavailability of tissue for molecular analysis, or failed gene expression profiling (GEP). (*) Risk factors were age < 40 years, mitotic rate > 0' mm², and tumor ulceration present. SLN, sentinel lymph node; SLNb, sentinel lymph node biopsy.
**FIG A2.** Double-loop cross-validation (DLCV) training-validation protocol in a schematic format. The DLCV consists of two nested cross-validation loops: in the inner loop (tenfold cross-validation), we estimate the optimal $\lambda$ parameter, namely, the weight of the LASSO penalty term (ie, optimal feature selection); in the outer loop (threefold cross-validation), we assess the performance of the classifier on each test set, with the $\lambda$ parameter as determined in the training set. Moreover, in each training set of the outer loop, we choose and fix an operating point on the receiver operating characteristic curve, and we assess the performance of the classifier at that operating point in the corresponding test set. The cross-validation procedure has been repeated 100 times, and unless otherwise stated, we reported the average performance over 300 test sets (three test sets per outer loop, repeated 100 times). LASSO, least absolute shrinkage and selection operator.

**FIG A3.** Clinicopathologic (CP) models for predicting sentinel lymph node metastasis. Average receiver operating characteristic curves for six different clinicopathologic models (CP models). CP1: Breslow thickness, age; CP2: Breslow thickness, age, Clark level, ulceration, biopsy location; CP3: Breslow thickness, age, ulceration, mitotic rate as a categorical variable (0, 1 to 6, or $>6$, mitosis per mm$^2$); CP4: Breslow thickness, age, ulceration, mitotic rate as a continuous variable; CP5: age mitotic rate, T categories; CP6: Breslow thickness, age, Clark level, mitotic rate, ulceration, angiolymphatic invasion, tumor-infiltrating lymphocytes, biopsy location (as in the MSKCC nomogram), regression, histologic type. AUC, area under the receiver operating characteristic curve; MSKCC, Memorial Sloan Kettering Cancer Center.
**FIG A4.** A combined clinicopathologic (CP) and molecular model for predicting sentinel lymph node metastasis. Blue line, model based on CP variables (CP model); red line, model based on gene expression profile (GEP model); teal line, model based on combined GEP and CP variables (CP-GEP model). For each receiver operating characteristic curve, the average area under the curve (AUC) is reported. Curves are averages over 300 double loop cross-validation–generated test sets.

**FIG A5.** Memorial Sloan Kettering Cancer Center (MSKCC) nomogram performance versus a combined clinicopathologic (CP) and gene expression profile (GEP). Orange line, model based on MSKCC nomogram; blue line, model based on CP variables (CP model); teal line, model based on gene expression and CP variables combined (CP-GEP model). For each receiver operating characteristic curve the average area under the curve (AUC) is reported. Curves are averages over 100 repeats obtained by concatenating the threefold cross-validation test results.
### TABLE A1. Clinicopathologic Variables Available for Statistical Modeling

| Clinicopathologic Variable | Value |
|----------------------------|-------|
| Sex                        | Female, male |
| Age                        | Years |
| Age categorical            | 15-39 years, 40-59 years, ≥ 60 years |
| Biopsy location            | Head and neck, trunk, upper extremity, lower extremity, acral |
| Biopsy location MSKCC      | Head and neck, trunk, extremity |
| Breslow thickness          | Millimeters |
| Breslow thickness categorical | < 1 mm, 1-2 mm, 2-4 mm |
| Mitotic rate categorical   | 0/mm², 1-6/mm², > 6/mm², not determined |
| Clark level                | II, III, IV, V |
| Ulceration                 | Yes, no, not determined |
| Regression                 | Yes, no, not determined |
| Tumor-infiltrating lymphocytes | Absent, nonbrisk, brisk, not determined |
| Microsatellitosis          | Yes, no, not determined |
| Angiolymphatic invasion    | Yes, no, not determined |
| Histology type             | Superficial spreading, nodular, desmoplastic, lentigo maligna, acral lentiginous, spindled, dermal, spitzoid, nevoid, unclassified, other, mixed, not determined |

Abbreviation: MSKCC, Memorial Sloan Kettering Cancer Center.

### TABLE A2. Performance Metrics

| Symbol | Definition | Equation |
|--------|------------|----------|
| TP     | True positive | TP/(TP + FN) |
| TN     | True negative | TN/(TN + FP) |
| FN     | False negative | FP/(TP + FN) |
| FP     | False positive | TP/(TP + FP) |
| SY     | Sensitivity | TP/(TP + FN) |
| SP     | Specificity | TN/(TN + FP) |
| NPV    | Negative predictive value | TN/(TN + FN) |
| PPV    | Positive predictive value | TP/(TP + FP) |
| ACC    | Accuracy | (TP + TN)/(TP + TN + FN + FP) |
| bACC   | Balanced accuracy | (SP + SY)/2 |
| SLNb RR | SLNb reduction rate | (TN + FN)/(TP + TN + FN + FP) |
| ER     | Error rate | FN/(TP + TN + FN + FP) |

Abbreviation: SLNb, sentinel lymph node biopsy.
**TABLE A3.** Classification of 197 Genes Evaluated by Quantitative Polymerase Chain Reaction

| Classification               | Genes                                                                 |
|------------------------------|----------------------------------------------------------------------|
| Control                      | ACTB, RPL8, RPLP0                                                      |
| Melanocyte lineage           | MAGEC1, MAGEC2, MITF, MLANA, PRAME, TYRP1                             |
| Other lineage                | KRT68, KRT14, KRT17, MND4, VIM                                         |
| Integrin adhesion receptors  | ITGA2, ITGA3, ITGA5, ITGA10, ITGB1, ITGB3, ITGB5, ITGB6, ITGB8       |
| Other cell surface receptors | ABO, ADAM12, CD31, CD44, CD47, CDH1, CDH2, CDH11, CNTN1, FLT1, LHFPL3, LRRC15, LYVE1, VCAN1 |
| Transport proteins           | ABCB5, FXYD3, KCNKL10, KCNQ5, NALCN, PIEZ02, SLC5A12, SLC24A2, TAPI1, TRPM1 |
| Signaling                    | ADIPOQ, BCL2L11, CAPN6, CORO2B, CTNNB1, DCLK1, DOK3, FOSL1, GPRC5B, HHTATL, HKDC1, LIM1, MYH4, MYH13, MYL9, NQD1, NID2, PIM2, PLAA27, PNNMA5, PORCN, PRKCA, PKRB, PTK2, PPP1R1A, RAPGEF3, RGS1, SMAD3, STAT3, SRC, STK40, TEK |
| Cell cycle and transcription | CDKN1A, CDKN2A, CREB3L1, MKI67, MYBL2, NR2E1, RARA, SXX2B, TBX5, TFAP2B, TFAP4, TP53, UPP1 |
| Fibronectin related          | FN1, SPP1, THSB1, THBS2, TNC                                          |
| Collagen related             | COL4A1, COL6A1, COL9A2, LOXL1, LOXL3, LOXL4, PLD3                     |
| Laminins                     | LAMA4, LAMB1, LAMB3                                                   |
| Tubulins                     | TUBA8, TUBB3                                                         |
| Proteinases and inhibitors   | ADAMTS19, MMP2, MMP3, MMP9, MMP10, MMP12, MMP14, PAPPA, PLAT, PLAU, SERPINB2, SERPINE1, SERPINE2, TFPI |
| TGF-β related                | ACVR1C, BMPR1B, GDF11, GDF15, INHBA, SMAD4, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR1, TGFBR2 |
| Growth factor related        | CCN2, EGRF, ERBB2, FGFR1, FGFR2, IGFR1, IGFBP2, IGFBP4, IGFBP5, LGALS1, NELL1, NGFR, NRP1, PDGFA, PTN, TGFα, VEGFA, VEGFR2, VEGFR3 |
| Immunity related             | CCL2, CCL18, CCL21, CD22, CD68, CD274, CTLA4, CXCL1, CXCL8, CXCL9, DCD, HAS2, IL1A, IL1B, IL6, MX1, OAS3, PDCD1, TRIL |
| Other extracellular matrix   | AGRN, AP0D, C22ORF34, CRTAC1, F5, FSTL3, FSTL5, GBP2, GSTM5, IVL, LG14, LEP, MMRAX5, NID1, MOBP, MUC7, PM02D1, OGN, RECK, SDC3, SPARC, SPRR4 |
| Pseudogenes                  | ACTG1P20, HNRRPAP1P33                                                 |

NOTE. Boldface genes (108 candidate biomarker and 3 control) were measured across a prospectively designed archival cohort of 754 patients. Abbreviation: TGF-β, tumor growth factor-β.

**TABLE A4.** Performance of CP, Molecular, and Combined Models

| Model                                      | P   | SY  | SP  | NPV | PPV | ACC | bACC | SLNRR | RR  | ER  |
|--------------------------------------------|-----|-----|-----|-----|-----|-----|------|-------|-----|-----|
| < 0.1 mm metastatic disease cases excluded (n = 754) |     |     |     |     |     |     |      |       |     |     |
| CP                                         | 0.17| 0.94| 0.32| 0.97| 0.22| 0.43| 0.63 | 0.28  | 0.01|     |
| GEP                                        | 0.17| 0.90| 0.43| 0.96| 0.25| 0.51| 0.67 | 0.37  | 0.02|     |
| CP-GEP                                     | 0.17| 0.90| 0.49| 0.96| 0.27| 0.56| 0.69 | 0.42  | 0.02|     |
| < 0.1 mm metastatic disease cases included (n = 795) |     |     |     |     |     |     |      |       |     |     |
| CP-GEP                                     | 0.21| 0.87| 0.50| 0.93| 0.32| 0.58| 0.68 | 0.42  | 0.03|     |

NOTE. Average performance of the CP, GEP, and combined CP-GEP models were trained in double-loop cross-validation 300 times. Performance is shown for the 754-patient cohort assembled on the basis of inclusion criteria and devoid of patients with equivocal SLN metastasis (ie, patients with < 0.1 mm metastatic disease). For comparison, we report the performance of the 754-patient cohort with all 41 cases of < 0.1 mm metastatic disease included. For this 795-patient cohort, the NPV dropped from 96% to 93% but was still well above 90%. The operating point of the models was determined in each training set to yield an NPV of 97.5% and was fixed to that value in the corresponding test set. Abbreviations: ACC, accuracy; bACC, balanced accuracy; CP, clinicopathologic; ER, error rate; GEP, gene expression profile; NPV, negative predictive value; P, fraction of patients with sentinel lymph node–positive outcomes (prevalence); PPV, positive predictive value; SLNRR, sentinel lymph node biopsy reduction rate; SP, specificity; SY, sensitivity.